Hexagon Capital Partners’s Integra LifeSciences IART Stock Holding History

Hexagon Capital Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-381	Closed	-$8.38K	–	826
2025 Q1	$8.38K	Hold	381	–	–	﹤0.01%	1025
2024 Q4	$8.64K	Sell	381 -85	-18%	-$1.85K	﹤0.01%	1055
2024 Q3	$8.47K	Sell	466 -22	-5%	-$510	﹤0.01%	965
2024 Q2	$14.2K	Sell	488 -452	-48%	-$13.4K	﹤0.01%	777
2024 Q1	$33.3K	Buy	940 +270	+40%	+$10.8K	0.01%	524
2023 Q4	$29.2K	Buy	670 +370	+123%	+$14.6K	0.01%	533
2023 Q3	$11.5K	Buy	300 +257	+598%	+$10.8K	﹤0.01%	708
2023 Q2	$1.77K	Sell	43 -102	-70%	-$4.91K	﹤0.01%	1100
2023 Q1	$8.32K	Sell	145 -137	-49%	-$7.72K	﹤0.01%	773
2022 Q4	$15.8K	Buy	282 +56	+25%	+$2.85K	﹤0.01%	606
2022 Q3	$10K	Buy	+226	New	+$11.6K	﹤0.01%	774

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hexagon Capital Partners's IART Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 381 shares — an estimated $8.38K sold.

Hexagon Capital Partners first reported a position in IART in Q3 2022 and held it in 11 quarters. The position peaked at $33.3K in Q1 2024. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.

Hexagon Capital Partners reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 381 Integra LifeSciences shares in Q2 2025, an estimated $8.38K.
Hexagon Capital Partners first reported a position in Integra LifeSciences in Q3 2022 and held it in 11 quarters.
Hexagon Capital Partners's Integra LifeSciences position peaked at $33.3K in Q1 2024.
208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.